
LinkMed
Innovative cancer therapy through advanced radioactive drugs, enhancing health and well-being.
Date | Investors | Amount | Round |
---|---|---|---|
investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | JPY300m Valuation: JPY7.5b | Series B | |
Total Funding | 000k |
Related Content
Link Med Co., Ltd. specializes in the development and manufacture of advanced radioactive drugs aimed at innovative cancer therapy. Operating in the healthcare and pharmaceutical market, Link Med serves hospitals, clinics, and medical research institutions. The company leverages cutting-edge science to create effective treatments that improve patient outcomes and overall well-being. Link Med's business model revolves around the production and sale of these specialized drugs, generating revenue through direct sales to healthcare providers and partnerships with medical institutions. The company is committed to advancing medical science and providing state-of-the-art solutions for cancer treatment.
Keywords: radioactive drugs, cancer therapy, healthcare, pharmaceutical, medical research, patient outcomes, advanced treatments, healthcare providers, medical institutions, innovative solutions.